Skip to Content

Huntington lab publications

Selected highlight publications

1. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Liau N, Shi W, Putz E, Stannard, K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou C.E, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Linossi, EM, Burns C.J, Carotta S, Gray DHD, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson, SE & Huntington ND. CIS is a potent checkpoint in NK cell-mediated tumour immunity. Nature Immunology 2016 2016. July 17(7):816-24.

2. Delconte RB, ShiW, Sathe P, Ushiki T, Seillet C, Minnich M, Kolesnik TB, Rankin LC, Mielke LA, Zhang JG, Busslinger M, Smyth MJ, Hutchinson DS, NuttSL, NicholsonSE, Alexander WS, Corcoran LM, Vivier, Belz GT, Carotta C, Huntington ND. Id2 governs natural killer cell fate by tuning their sensitivity to IL-15. Immunity. 2016. Jan 12; 44:1.

3. Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol. 2019 Feb;40(2):142-158

4. Viant C, Guia S, Hennessy RJ, Rautela J, Pham K, Bernat C, Goh W, Jiao Y, Delconte R, Roger M, Simon V, Souza-Fonseca-Guimaraes F, Grabow S, Belz GT, Kile BT, Strasser A, Gray D, Hodgkin PD, Beutler B, Vivier E, Ugolini S, Huntington ND. Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. J Exp Med. 2017 Feb;214(2):491-510.

5. Jiao Y, Davis JE, Rautela J, Carrington EM, Ludford-Menting MJ, Goh W, Delconte RB, Souza
Fonseca-Guimaraes F, Koldej R, Gray D, Huang D, Kile BT, Lew AM, Ritchie DS, Huntington ND.
Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. Cell Death Differ. 2018 Nov 12.

Additional publications

A full list of Huntington Lab publications can be viewed on Monash research profile